ClinicalTrials.gg
CompletedNCT07519525Updated Jun 8, 2026

A Study of [14C]-LY4064809 in Healthy Participants

A Phase 1 interventional study of LY4064809 and [14C]-LY4064809 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be healthy as shown by medical history, physical examination, laboratory tests and heart monitoring
  • Must have normal blood pressure and pulse rate
  • Must have a history of a minimum of 1 bowel movement per day
  • Must have (BMI) between 18 and 32 kilograms per square meter (kg/m2)
  • Must be healthy men or healthy women who are not of
  • Healthy men with partners who can become pregnant must remain abstinent or use consistent with local regulations

Exclusion criteria

Exclusion Criteria:

  • Must not have a significant history or presence of metabolic disease, heart, liver, gallbladder, bile ducts, digestive, blood or nervous system disorders that could affect the way the body absorbs and processes the study drug
  • Must not have an abnormal (ECG)
  • Must not have a history of major surgery within 30 days of entering study
  • Must not have a history of cancer within 5 years of screening
  • Must not have known allergies to LY4064809 or related compounds
  • Must not have history of multiple or severe drug reactions or allergies which required treatment with or epinephrine
  • Must not have history or presence of psychiatric conditions that would prevent the participant from following study instructions.
  • Must not use medications, except acetaminophen within 14 days of the first dose of LY4064809 and during the clinic stay
  • Must not have participated in and been dosed in more than 2 radiolabeled drug studies in the last 12 months
  • Must not have had exposure to significant diagnostic, therapeutic or employment-related radiation within 12 months
  • Must not have participated in any other radiolabeled study drug trial within 6 months prior to admission.
  • Must not show evidence of (HIV) infection or positive HIV-1 and HIV-2 antibodies
  • Must not have evidence of virus (HCV) infection or a positive HCV antibody test.
  • Must not have evidence of virus (HBV) infection or a positive Hepatitis B surface antigen (HBsAg)
  • Must not have alcohol intake deemed significant by the investigator
  • Must not use tobacco, smoking-cessation products, e-cigarettes (nicotine and non-nicotine), or nicotine products within 90 days prior to LY4064809 administration and discharge from the clinical research unit (CRU) or early termination (ET)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    LY4064809

    Drug: LY4064809 · Drug: [14C]-LY4064809

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the absolute bioavailability (F) of LY4064809 following administration of a single oral dose compared to an intravenous reference dose in healthy participants.

    Time frame: Baseline up to Day 14

Secondary outcomes

  1. Pharmacokinetics (PK): Plasma Maximum Concentration (Cmax) of LY4064809

    PK: Plasma Cmax of LY4064809

    Time frame: Baseline up to Day 14

  2. PK of Total Radioactivity: Plasma Area Under the Concentration Versus Time Curve (AUC) of [14C]-LY4064809

    PK of Total Radioactivity: Plasma AUC

    Time frame: Baseline up to Day 14

  3. Excretion and Recovery of Total Radioactivity in Urine

    Investigate the rate and routes of excretion, including the mass balance in urine after dosing.

    Time frame: Baseline up to Day 13

  4. Excretion and Recovery of Total Radioactivity and [14C] LY4064809 in Feces

    Investigate the rate and routes of excretion, including the mass balance in feces

    Time frame: Baseline up to Day 13

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc. - Madison
    Madison, Wisconsin 53704-2526, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in May 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Apr 9, 2026
StartActual
Mar 27, 2026
Primary completionActual
May 26, 2026
CompletionActual
May 26, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519525
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Mar 27, 2026
Primary completion
May 26, 2026
Completion
May 26, 2026
Last update
Jun 8, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STX-478

Start the discussion